Savara Inc. is a clinical-stage biopharmaceutical company developing MOLBREEVI, an inhaled biologic based on granulocyte-macrophage colony-stimulating factor (GM-CSF) delivered via a proprietary nebulizer system for treating autoimmune pulmonary alveolar proteinosis (autoimmune PAP), a rare lung disease with no approved pharmaceutical treatments. The company operates through outsourced manufacturing partners and has secured global rights to the drug-device combination, with intellectual property protection extending more than a decade. Savara's commercialization strategy relies on direct sales to specialists and key medical centers upon regulatory approval, supplemented by a royalty-sharing agreement with a strategic investor, with the goal of establishing itself as a leader in rare respiratory therapeutics and addressing the significant unmet medical need in this patient population.